Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 167-178 , February 2010

Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues

Received 14 March 2009 ,Revised 10 September 2009 ,Accepted 16 October 2009.

References 

  1. Lucignani G. Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213. Eur J Nucl Med Mol Imaging. 2008;35:1729–1733
  2. Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol. 2007;34:779–785
  3. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted alpha-particle therapy. J Nucl Med. 2005;46(Suppl 1):199S–204S
  4. Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal JF, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging. 2005;32:601–614
  5. Imam SK. Advancements in cancer therapy with alpha-emitters: a review. Int J Rad Oncol Biol Phys. 2001;51:271–278
  6. Brechbiel MW. Targeted alpha-therapy: past, present, future?. Dalton Trans. 2007;4918–4928
  7. Wilbur DS. Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconjug Chem. 1992;3:433–470
  8. Kabalka GW, Varma RS. The synthesis of radiolabeled compounds via organometallic intermediates. Tetrahedron. 1989;45:6601–6621
  9. Moerlein SM. Regiospecific incorporation of no-carrier-added radiobromine and radioiodine into aromatic rings via halogenodegermylation. J Chem Soc Perkin Trans I. 1985;1687–1692
  10. Wilbur DS. [211At]Astatine-labeled compound stability: issues with released [211At]astatide and development of labeling reagents to increase stability. Curr Radiopharm. 2008;1:144–176
  11. Wilbur DS, Chyan MK, Hamlin DK, Vessella RL, Wedge TJ, Hawthorne MF. Reagents for astatination of biomolecules: 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination. Bioconjug Chem. 2007;18:1226–1240
  12. Wilbur DS, Chyan MK, Hamlin DK, Kegley BB, Risler R, Pathare PM, et al. Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds. Bioconjug Chem. 2004;15:203–223
  13. Wilbur DS, Hamlin DK, Chyan MK, Kegley BB, Quinn J, Vessella RL. Biotin reagents in antibody pretargeting: 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives. Bioconjug Chem. 2004;15:601–616
  14. Wilbur DS, Hamlin DK, Srivastava RR, Chyan MK. Synthesis, radioiodination, and biodistribution of some nido- and closo-monocarbon carborane derivatives. Nucl Med Biol. 2004;31:523–530
  15. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, et al. Comparative metabolism and retention of iodine-125, yttrium-90, indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123–2129
  16. Duncan JR, Welch MJ. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med. 1993;34:1728–1738
  17. Stein R, Goldenberg DM, Thorpe SR, Basu A, Mattes MJ. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Cancer Res. 1995;55:3132–3139
  18. Hawthorne MF, Maderna A. Applications of radiolabeled boron clusters to the diagnosis and treatment of cancer. Chem Rev. 1999;99:3421–3434
  19. Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Codogni IM, et al. The chemistry of neutron capture therapy. Chem Rev. 1998;98:1515–1562
  20. Akizawa H, Uehara T, Arano Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev. 2008;60:1319–1328
  21. Akizawa H, Arano Y. Altering pharmacokinetics of radiolabeled antibodies by the interposition of metabolizable linkages. Metabolizable linkers and pharmacokinetics of monoclonal antibodies. Q J Nucl Med. 2002;46:206–223
  22. Wilbur DS, Chyan MK, Hamlin DK, Perry MA. Reagents for astatination of biomolecules: 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211. Bioconjug Chem. 2009;20:591–602
  23. Knoth WH. Chemistry of boranes: XXXI. 1,10-Bis(hydroxymethyl)octachlorodecaborate (2-). J Am Chem Soc. 1967;89:4850–4852
  24. Kaplan HM, Brewer NR, Blair WH. Physiology. In:  Foster HL,  Small JD,  Fox JG editor. The Mouse in Biomedical Research. New York: Academic Press; 1983;p. 248–292
  25. Knoth WH, Sauer JC, Balthis JH, Miller HC, Muetterties EL. Chemistry of boranes: XXX. Carbonyl derivatives of B10H102− and B12H122−. J Am Chem Soc. 1967;89:4842–4850
  26. Knoth WH, Sauer JC, England DC, Hertler WR, Muetterties EL. Chemistry of boranes: XIX. Derivative chemistry of B10H10−2 and B12H12−2. J Am Chem Soc. 1964;86:3973–3983
  27. Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, et al. Biodistributions, myelosuppression and toxicities in mice treated with an anti-CD45 antibody labeled with the α-emitting radionuclides bismuth-213 or astatine-211. Cancer Res. 2009;69:2408–2415
  28. Paik CH, Yokoyama K, Reynolds JC, Quadri SM, Min CY, Shin SY, et al. Reduction of background activities by introduction of a diester linkage between antibody and a chelate in radioimmunodetection of tumor. J Nucl Med. 1989;30:1693–1701
  29. Weber RW, Boutin RH, Nedelman MA, Lister-James J, Dean RT. Enhanced kidney clearance with an ester-linked 99mTc-radiolabeled antibody Fab′-chelator conjugate. Bioconjug Chem. 1990;1:431–437
  30. Arano Y, Matsushima H, Tagawa M, Koizumi M, Endo K, Konishi J, et al. A novel bifunctional metabolizable linker for the conjugation of antibodies with radionuclides. Bioconjug Chem. 1991;2:71–76
  31. Tibben JG, Massuger LFAG, Boerman OC, Claessens RAMJ, Borm GF, Pak KY, et al. Decreased kidney uptake of technetium-99m-labelled Fab′ fragments in ovarian carcinoma bearing nude mice using a cleavable chelator. Nucl Med Biol. 1994;21:17–24
  32. Meares CF, McCall MJ, Deshpande SV, DeNardo SJ, Goodwin DA. Chelate radiochemistry: cleavable linkers lead to altered levels of radioactivity in the liver. Int J Cancer. 1988;2:99–102
  33. Peterson JJ, Meares CF. Cathepsin substrates as cleavable peptide linkers in bioconjugates, selected from a fluorescence quench combinatorial library. Bioconjug Chem. 1998;9:618–626
  34. Kumaresan PR, Natarajan A, Song A, Wang X, Liu R, DeNardo G, et al. Development of tissue plasminogen activator specific “on demand cleavable” (odc) linkers for radioimmunotherapy by screening one-bead-one-compound combinatorial peptide libraries. Bioconjug Chem. 2007;18:175–182
  35. West KR, Otto S. Reversible covalent chemistry in drug delivery. Curr Drug Discov Technol. 2005;2:123–160
  36. Ulbrich K, Subr V. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev. 2004;56:1023–1050
  37. Kratz F, Beyer U, Schutte MT. Drug-polymer conjugates containing acid cleavable bonds. Crit Rev Ther Drug Carrier Syst. 1999;16:245–288
  38. Lapeyre M, Leprince J, Massonneau M, Oulyadi H, Renard PY, Romieu A, et al. Aryldithioethyloxycarbonyl (Ardec): a new family of amine protecting groups removable under mild reducing conditions and their applications to peptide synthesis. Chemistry. 2006;12:3655–3671
  39. Elias H, Arnold C, Kloss G. Preparation of 131I-labelled m-iodohippuric acid and its behaviour in kidney function studies compared to o-iodohippuric acid. Int J Appl Radiat Isot. 1973;24:463–469
  40. De Duve C, De Barsy T, Polle B, Trouet A, Tulkens P, Van Hoof F. Lysosomotropic agents. Biochem Pharm. 1974;23:2495–2531
  41. Mueller BM, Wrasidlo WA, Reisfeld RA. Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers. Bioconjug Chem. 1990;1:325–330
  42. Kaneko T, Willner D, Monkovic I, Knipe JO, Braslawsky GR, Greenfield RS, et al. New hydrazone derivatives of adriamycin and their immunoconjugates — a correlation between acid stability and cytotoxicity. Bioconjug Chem. 1991;2:133–141

PII: S0969-8051(09)00252-2

doi: 10.1016/j.nucmedbio.2009.10.004

Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 167-178 , February 2010

Article Tools

* Image Usage & Resolution